{"url_path":"/sec/sxtp/8-k/2026-07-20/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1946563/0001213900-26-079612-index.html","accession_number":"0001213900-26-079612","cik":"0001946563","ticker":"SXTP","issuer_name":"60 DEGREES PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1946563/0001213900-26-079612-index.html","primary_entity_key":"0001946563","primary_entity_name":"60 DEGREES PHARMACEUTICALS, INC."},"word_count":87,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements\nand Exhibits**\n\n** **\n\n(a) Exhibits** **\n\n \n\n**Number**\n \n**Description**\n\n99.1\n \n[60 Degrees Pharmaceuticals, Inc. Investor Presentation, dated July 20, 2026](ea029850501ex99-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n1\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n \n**60 DEGREES PHARMACEUTICALS, INC.**\n\n \n \n\nDate: July 20, 2026\nBy:\n*/s/ Geoffrey Dow*\n\n \nName:\nGeoffrey Dow\n\n \nTitle:\nChief Executive Officer and President\n\n \n\n2"}